The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Immunoglobulin E (IgE) plays a central role in allergic responses, yet therapeutic targeting of IgE with antibodies such as omalizumab is met with various limitations. Here the authors characterize the molecular properties and crystal structure of a new anti-IgE antibody, ligelizumab, for mechanisti...
Guardado en:
Autores principales: | Pascal Gasser, Svetlana S. Tarchevskaya, Pascal Guntern, Daniel Brigger, Rahel Ruppli, Noemi Zbären, Silke Kleinboelting, Christoph Heusser, Theodore S. Jardetzky, Alexander Eggel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e445acdbe9e24d959b171d05c7983a61 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Luke F. Pennington, et al.
Publicado: (2016) -
Current and future applications of the anti-IgE antibody omalizumab
por: Cristoforo Incorvaia, et al.
Publicado: (2008) -
Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex
por: Luke F. Pennington, et al.
Publicado: (2021) -
Development and characterization of a unique anti‐IgE mouse monoclonal antibody cross‐reactive between human and canine IgE
por: Akiko Kumagai, et al.
Publicado: (2021) -
IgG1 memory B cells keep the memory of IgE responses
por: Jin-Shu He, et al.
Publicado: (2017)